Technical Analysis for CIR - Circassia Pharmaceutical

Grade Last Price % Change Price Change
F 24.6 -0.20% -0.05
CIR closed down 3.33 percent on Wednesday, January 27, 2021, on 1.94 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical CIR trend table...

Date Alert Name Type % Chg
Stochastic Reached Oversold Weakness -0.20%
Outside Day Range Expansion -0.20%
Oversold Stochastic Weakness -0.20%
Narrow Range Bar Range Contraction -3.53%
Inside Day Range Contraction -3.53%
Oversold Stochastic Weakness -1.60%
Narrow Range Bar Range Contraction -3.53%
NR7 Range Contraction -3.53%
Oversold Stochastic Weakness -3.53%
Volume Surge Other -3.15%
Older End-of-Day Signals for CIR ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Circassia Pharmaceutical Description

Circassia Pharmaceuticals plc is a specialty biopharmaceutical company focused on allergy and respiratory diseases. The Company operates through three segments: Allergy, which relates to a range of immunotherapy development products for the treatment of allergy; NIOX, which relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO), and Respiratory, which relates to the portfolio of asthma and chronic obstructive pulmonary disease product candidates. Its next-generation immunotherapy is in Phase III testing for cat allergy. Its lead asthma treatment targets substitution of GlaxoSmithKline's (GSK's) Flixotide pMDI. It is developing therapies targeting direct substitution of Seretide pMDI and Serevent pMDI. The Company is also developing a range treatment, including a fixed dose triple combination containing an inhaled corticosteroid, long-acting beta agonist and long-acting muscarinic antagonist.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Target Pharmaceutical Medicine Pharmaceuticals Disease Testing Targeting Diseases Medical Specialties Therapy Oxide Smith Beta Biopharmaceutical Respirator Therapies Immunology Immune System Respiratory Disease Allergy Chronic Obstructive Pulmonary Disease Respiratory Diseases Immunotherapy Organ Systems Respiratory Therapy Glaxosmithkline Asthma Long Acting Beta Adrenoceptor Agonist

Is CIR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Indicators

Indicator Value
52 Week High 33.4025
52 Week Low 0.255
Average Volume 981,142
200-Day Moving Average 26.24
50-Day Moving Average 27.12
20-Day Moving Average 26.62
10-Day Moving Average 25.37
Average True Range 1.42
ADX 16.8
+DI 15.18
-DI 16.70
Chandelier Exit (Long, 3 ATRs ) 25.75
Chandelier Exit (Short, 3 ATRs ) 28.30
Upper Bollinger Band 29.39
Lower Bollinger Band 23.84
Percent B (%b) 0.15
BandWidth 20.88
MACD Line -0.57
MACD Signal Line -0.35
MACD Histogram -0.2165
Fundamentals Value
Market Cap 97.98 Million
Num Shares 397 Million
EPS -33.70
Price-to-Earnings (P/E) Ratio -0.73
Price-to-Sales 1.93
Price-to-Book 1.59
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 26.74
Resistance 3 (R3) 26.96 26.48 26.39
Resistance 2 (R2) 26.48 25.95 26.37 26.28
Resistance 1 (R1) 25.56 25.62 25.33 25.35 26.16
Pivot Point 25.09 25.09 24.97 24.98 25.09
Support 1 (S1) 24.17 24.55 23.93 23.95 23.14
Support 2 (S2) 23.69 24.22 23.58 23.02
Support 3 (S3) 22.78 23.69 22.91
Support 4 (S4) 22.56